Ongoing research is exploring a combination immunotherapy approach using both ipilimumab, a monoclonal antibody that inhibits the tumor-promoting activity of CTLA4, and PD-1/PD-L1 blockers for potential effectiveness in ccRCC immunotherapy [73]. Here, CTLA4 is linked to nonpapillary renal cell carcinoma.